| 國立成功大學 |
2024-12 |
Characteristics of Successful Leadership: Perspectives From Asian Nursing Leaders
|
Im;Eun-Ok;Chen;Ching-Min;Kim;Haewon;Oh;Geum, Eui;Sakashita;Reiko;Wang;Hsiu-Hung;Tsai;Hsiu-Min |
| 國立成功大學 |
2024-12 |
Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
|
Xu;Binghe;Wang;Shusen;Yan;Min;Sohn;Joohyuk;Li;Wei;Tang;Jinhai;Wang;Xiaojia;Wang;Ying;Im;Seock-Ah;Jiang;Dongdong;Valdez;Theresa;Dasgupta;Anandaroop;Zhang;Yiran;Yan;Yilin;Komatsubara;Kimberly, M.;Chung;Wei-Pang;Ma;Fei;Dai;Ming-Shen |
| 國立成功大學 |
2024-12 |
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
|
Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A. |
| 國立成功大學 |
2024-10-10 |
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
|
Yao;Herui;Yan;Min;Tong;Zhongsheng;Wu;Xinhong;Ryu;Min-Hee;Park;John, John J.;Kim;Hyun, Jee;Zhong;Yahua;Zhao;Yiming;Voskoboynik;Mark;Yin;Yongmei;Liu;Kan;Kaubisch;Andreas;Liu;Caigang;Zhang;Jian;Wang;Shouman;Im;Seock-Ah;Ganju;Vinod;Barve;Minal;Li;Hui;Ye;Changsheng;Roy;Amitesh, C.;Bai;Li-Yuan;Yen;Chia-Jui;Gu;Shanzhi;Lin;Yung-Chang;Wu;Lingying;Bao;Lequn;Zhao;Kaijing;Shen;Yu;Rong;Shangyi;Zhu;Xiaoyu;Song;Erwei |
| 國立成功大學 |
2024-10 |
Dato-DXd vs. chemotherapy for patients with inoperable/ metastatic HR+/HER2L breast cancer: TROPION-Breast01 Asian subset
|
Tsurutani;J;Hattori;M;Im;S;Wang;S;Lu;Y;Sohn;J;Zhang;Q;Park;Y;Lee;K;Ozaki;Y;Jiang;Z;Chung;W;Laurentiis, De;M;Pernas;S;Xu;L;Khan;S;Denduluri;N;Pistilli;B;Bardia;A;Xu;B |
| 國立成功大學 |
2024-09 |
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
|
Iwata;Hiroji;Xu;Binghe;Kim;Sung-Bae;Chung;Wei-Pang;Park;Hee, Yeon;Kim;Hwan, Min;Tseng;Ling-Ming;Chung;Chi-Feng;Huang;Chiun-Sheng;Kim;Hyun, Jee;Chiu;Yan, Joanne Wing;Yamashita;Toshinari;Li;Wei;Egorov;Anton;Nishijima;Soichiro;Nakatani;Shunsuke;Nishiyama;Yuji;Sugihara;Masahiro;Cortes;Javier;Im;Seock-Ah |
| 國立成功大學 |
2024-08-10 |
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
|
Lu;Yen-Shen;Mahidin;Mohd, Eznal Izwadi Bin;Azim;Hamdy;Eralp;Yesim;Yap;Sim, Yoon;Im;Seock-Ah;Rihani;Julie;Gokmen;Erhan;Bastawisy, El;Ahmed;Karadurmus;Nuri;Lim;Ni, Yueh;Lim;Sen, Chun;Duc;Thanh, Le;Chung;Wei-Pang;Babu;Govind, K.;Penkov;Konstantin;Bowles;James;Alfaro;Delgar, Teresa;Wu;Jiwen;Gao;Melissa;Slimane;Khemaies;Saghir, El;Nagi, S. |
| 國立成功大學 |
2024-07~2024-09 |
Current Status of Translational Science in Nursing Across Four Countries
|
Tsai;Hsiu-Min;Wang;Hsiu-Hung;Sakashita;Reiko;Oh;Geum, Eui;Chen;Ching-Min;Im;Eun-Ok |
| 國立成功大學 |
2024-06-1 |
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer
|
Bhave;Manali, A.;Jhaveri;Komal, L.;Kaufman;Peter, A.;Aftimos;Georges, Philippe;Lombard;Margaret, Janine;Sideras;Kostandinos;Im;Seock-Ah;Ma;Cynthia, X.;Lee;Kuo-Ting;Kim;Sung-Bae;Li;Yujia;Yuen;Eunice;Estrem;Shawn, T.;Nguyen;Bastien;Bacchion;Francesca;Ismail-Khan;Roohi;Beeram;Muralidhar;Sohn;Joohyuk |
| 國立成功大學 |
2024-06 |
Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
|
Hsu;C-H;Dziadziuszko;R;Abreo, Gomez;D, A.;Aksoy;S;Martin, Gil;M;Roderburg;C;Yen;C, J.;Arican;A;Cassier;P;Im;S-A;Kim;S-B;Kudo;T;Ochsenreither;S;Sendur;M, A. N.;Yonemori;K;Rojas;C, I.;Liu;Q;Keenan;T;Healy;J;Kwiatkowski;M |
| 國立成功大學 |
2024-05 |
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
|
Hurvitz;S, A.;Kim;S, -B.;Chung;W, -P.;Im;S, -A.;Park;Y, H.;Hegg;R;Kim;M, -H.;Tseng;L, -M.;Petry;V;Chung;C, -F.;Iwata;H;Hamilton;E;Curigliano;G;Xu;B;Egorov;A;Liu;Y;Cathcart;J;Bako;E;Tecson;K;Verma;S;Cortes;J |
| 國立成功大學 |
2024 |
Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
|
Xu;B;Wang;S;Yan;M;Sohn;J;Li;W;Tang;J;Wang;X;Wang;Y;Im;S, -A.;Jiang;D;Valdez;T;Dasgupta;A;Zhang;Y;Yan;Y;Komatsubara;K, M.;Chung;W, -P.;Ma;F;Dai;M, -S. |
